Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001080272 | SCV000644454 | benign | Tuberous sclerosis 2 | 2024-10-31 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000833206 | SCV000974967 | likely benign | not provided | 2018-06-19 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Genome- |
RCV001080272 | SCV002039342 | benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV002256375 | SCV002533424 | likely benign | Hereditary cancer-predisposing syndrome | 2021-01-01 | criteria provided, single submitter | curation | |
Ambry Genetics | RCV002256375 | SCV002618156 | likely benign | Hereditary cancer-predisposing syndrome | 2020-02-27 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
All of Us Research Program, |
RCV003999293 | SCV004833425 | likely benign | Tuberous sclerosis syndrome | 2023-12-13 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004735615 | SCV005356975 | likely benign | TSC2-related disorder | 2024-06-25 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |